Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.
Miners
J O
JO
Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University School of Medicine, Adelaide, Australia. john.miners@flinders.edu.au
Coulter
S
S
Birkett
D J
DJ
Goldstein
J A
JA
D001189:Aryl Hydrocarbon Hydroxylases; D065729:Cytochrome P-450 CYP2C9; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004232:Diuretics / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D014644:Genetic Variation; D006801:Humans; D008862:Microsomes, Liver / Q000201:enzymology; D012441:Saccharomyces cerevisiae / Q000201:enzymology; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000037:antagonists & inhibitors / Q000235:genetics*; D013426:Sulfaphenazole / Q000494:pharmacology; D013449:Sulfonamides / Q000378:metabolism*; D000077786:Torsemide
D065607:Cytochrome P-450 Enzyme Inhibitors; D004232:Diuretics; D004791:Enzyme Inhibitors; D013449:Sulfonamides; C400322:cytochrome P-450 CYP2C subfamily; D013426:Sulfaphenazole; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D039181:Steroid 16-alpha-Hydroxylase; D000077786:Torsemide